News - Regulation, Alkermes

Filter

Current filters:

RegulationAlkermes

Popular Filters

FDA approves Bydureon Pen for type 2 diabetes

FDA approves Bydureon Pen for type 2 diabetes

03-03-2014

Anglo-Swedish drug major AstraZeneca says the US Food and Drug Administration has approved the Bydureon…

AlkermesAmylinAstraZenecaBristol-Myers SquibbBydureonDiabetesPharmaceuticalRegulationUSA

FDA approves Otsuka and Lundbeck's once-monthly Abilify Maintena for schizophrenia

01-03-2013

Japanese drugmaker Otsuka Pharmaceutical (TYO: 4578) and Danish partner Lundbeck (LUND: DC) have received…

Abilify MaintenaAlkermesLundbeckNeurologicalNorth AmericaOtsukaPharmaceuticalRegulation

Alkermes pulls MAA for Megestrol product

13-03-2012

The European Medicines Agency says it has been formally notified by the Irish subsidiary of US drugmaker…

AlkermesAnti-viralsEuropeMegestrolOncologyPharmaceuticalRegulation

FDA finally approves Bydureon

30-01-2012

There was good news on Friday for USA-based Amylin Pharmaceuticals (Nasdaq: AMLN) and Alkermes (Nasdaq:…

AlkermesAmylinBydureonDiabetesEli LillyNorth AmericaPharmaceuticalRegulation

US FDA sets PDUFA action dates for Bydureon and peginesatide

12-08-2011

US drugmakers Amylin Pharmaceuticals (Nasdaq: AMLN), Eli Lilly (NYSE: LLY) and Alkermes (Nasdaq: ALKS)…

AffymaxAlkermesAmylinBydureonDiabetesEli LillyNorth AmericaOncologypeginesatidePharmaceuticalRegulationTakeda Pharmaceuticals

Back to top